EMEA-002640-PIP01-19-M01 - paediatric investigation plan

cendakimab

Key facts

• Active substance:
  cendakimab
• Therapeutic area:
  Immune system disorders
• Decision number:
  P/0522/2023
• PIP number:
  EMEA-002640-PIP01-19-M01
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of eosinophilic esophagitis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  29/12/2023
• Compliance check done:
  No

Decision

P/0522/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for cendakimab (EMEA- 002640-PIP01-19-M01)

Reference Number: EMA/553394/2023